Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery.
AuthorsHudson, Andrew M
Trotter, Eleanor W
Chapman, Philip J
Lorigan, Paul C
Miller, Crispin J
AffiliationSignalling Networks in Cancer, Cancer Research UK Manchester Institute.
MetadataShow full item record
AbstractCancer genome sequencing is being employed at an increasing rate to identify actionable driver mutations that can inform therapeutic intervention strategies. A comparison of two of the most prominent cancer genome sequencing databases from different institutes (CCLE and COSMIC) revealed marked discrepancies in the detection of missense mutations in identical cell lines (57.38% conformity). The main reason for this discrepancy is inadequate sequencing of GC-rich areas of the exome. We have therefore mapped over 400 regions of consistent inadequate sequencing (cold-spots) in known cancer-causing genes and kinases in which neither institute find mutations. We demonstrate, using a newly identified PAK4 mutation as proof of principle, that specific targeting and sequencing of these GC-rich cold-spot regions can lead to the identification of novel driver mutations in known tumor suppressors and oncogenes. We highlight that cross-referencing between genomic databases is required to comprehensively assess genomic alterations in commonly used cell lines and that there are still significant opportunities to identify novel drivers of tumorigenesis in poorly sequenced areas of the exome. Finally we assess other reasons for the observed discrepancy, such as variations in dbSNP filtering and the acquisition/loss of mutations, to give explanations as to why there is discrepancy in pharmacogenomic studies given recent concerns with poor reproducibility of data.
CitationDiscrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery. 2014: Cancer Res
- Exome sequencing reveals comprehensive genomic alterations across eight cancer cell lines.
- Authors: Chang H, Jackson DG, Kayne PS, Ross-Macdonald PB, Ryseck RP, Siemers NO
- Issue date: 2011
- [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
- Authors: Pécuchet N, Legras A, Laurent-Puig P, Blons H
- Issue date: 2016 Jan
- Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure.
- Authors: Tokheim C, Bhattacharya R, Niknafs N, Gygax DM, Kim R, Ryan M, Masica DL, Karchin R
- Issue date: 2016 Jul 1
- Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.
- Authors: Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, Verhaak RG, Zhang F, Karchin R, Liu CG, Lu KH, Broaddus RR, Scott KL, Hennessy BT, Mills GB
- Issue date: 2012 Nov
- Analysis of 7,815 cancer exomes reveals associations between mutational processes and somatic driver mutations.
- Authors: Poulos RC, Wong YT, Ryan R, Pang H, Wong JWH
- Issue date: 2018 Nov